Newly-Launched Portable Molecular Diagnostic Platform Detects COVID-19 at Point-of-Care within 30 Minutes
Posted on 15 Oct 2021
A new portable molecular diagnostic platform and its compatible diagnostic test for the detection of SARS-CoV-2 delivers results within 30 minutes at the Point-of-Care (POC).
BIOPIX-T (Voutes, Greece) has launched its portable molecular diagnostic platform, the PEBBLE qcLAMP Platform, along with its compatible diagnostic test for the detection of the SARS-CoV-2 virus. PEBBLE is the first Greek portable molecular diagnostic device based on LAMP technology (Isothermal PCR), which can be used at the POC. PEBBLE as well as COV19 qcLAMP kit, the corresponding diagnostic kit to be used together with the diagnostic instrument for the detection of SARS-CoV-2, are now CE Marked.
The reliability of the PEBBLE device is comparable to the corresponding laboratory ‘reference devices’, which cost nevertheless tens of times more and cannot be transported to the points of interest. This offers to the responsible authorities an excellent new weapon for management of the pandemic as they will be able to perform rapid (within 30 minutes) and much more reliable molecular tests at a cost comparable to that of rapid tests. Other innovative features of the device are expected to be gradually certified and utilized, such as the ability to perform tests on a saliva sample, without the unpleasant current sampling procedure.
“BIOPIX-T’s innovative molecular diagnostic device can be a catalyst, giving a very fast, cost-effective and at the same time reliable result to all points of care as well as other points of interest, such as airports, cruise ships, companies, community services, but also hotels, border entry points or immigration hot-spots, etc.,” said George Papadakis who leads BIOPIX-T.
Related Links:
BIOPIX-T
